Observational studyTranslational neurodegeneration2021
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease.
Observational study in Translational neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".International journal of environmental research and public health · 2022Pooled it
- The emergence of neuropsychiatric symptoms in preclinical Alzheimer's disease: An emotion regulation perspective.Neuron · 2026Review
- Dynamic trajectories of neuropsychiatric symptoms predict Alzheimer's disease risk and clinical phenotypes.General psychiatry · 2026Article
- Early prediction of Alzheimer's disease using longitudinal electronic health records of US military veterans.Communications medicine · 2026Article
- Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review.Frontiers in pharmacology · 2026Review
- Effect of combined transcranial direct current stimulation and cognitive training on brain microstructure and network homogeneity in late-life depression: a pilot study.Journal of affective disorders reports · 2025Article
- Change in Depressive Symptoms and Longitudinal Regional Amyloid Accumulation in Unimpaired Older Adults.JAMA network open · 2024Article
- Impaired sleep is associated with tau deposition onJournal of the neurological sciences · 2024Article
- Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Neuropsychiatric Symptoms are Related to Blood-biomarkers in Major Neurocognitive Disorders.Current aging science · 2024Article
- APOE Gene Associated with Dementia-Related Traits, Depression, and Anxiety in the Hispanic Population.Genes · 2023Article
- CNS Organoid Surpasses Cell-Laden Microgel Assembly to Promote Spinal Cord Injury Repair.Research (Washington, D.C.) · 2022Article
- Alzheimer's Disease and Empathic Abilities: The Proposed Role of the Cingulate Cortex.Journal of Alzheimer's disease reports · 2021Review
- Neuropsychiatric Symptoms Mediated the Relationship Between Odor Identification and Cognition in Alzheimer's Disease Spectrum: A Structural Equation Model Analysis.Frontiers in aging neuroscience · 2021Article
- Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundNeuropsychiatric symptoms (NPS) are increasingly recognized as early non-cognitive manifestations in the Alzheimer's disease (AD) continuum. However, the role of NPS as an early marker of pathophysiological progression in AD remains unclear. Dominantly inherited AD (DIAD) mutation carriers are young individuals who are destined to develop AD in future due to the full penetrance of the genetic mutation. Hence, the study of DIAD mutation carriers enables the evaluation of the associations between pure AD pathophysiology and metabolic correlates of NPS without the confounding effects of co-existing pathologies. In this longitudinal study, we aimed to identify regional brain metabolic dysfunctions associated with NPS in cognitively intact DIAD mutation carriers.
methodsWe stratified 221 cognitively intact participants from the Dominantly Inherited Alzheimer's Network according to their mutation carrier status. The interactions of NPS measured by the Neuropsychiatric Inventory-Questionnaire (NPI-Q), age, and estimated years to symptom onset (EYO) as a function of metabolism measured by [
resultsA total of 119 mutation carriers and 102 non-carriers were studied. The interaction of higher NPI-Q and shorter EYO was associated with more rapid declines of global and regional [
conclusionsThe NPS in cognitively intact DIAD mutation carriers may be a clinical indicator of subsequent metabolic decline in brain networks vulnerable to AD, which supports the emerging conceptual framework that NPS represent early manifestations of neuronal injury in AD. Further studies using different methodological approaches to identify NPS in preclinical AD are needed to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.